CRYOCOR UPDATES FDA REVIEW OF ATRIAL FLUTTER PMA

CryoCor, Inc., a medical device company focused on the treatment of cardiac arrhythmias, announced today an update to the status of its atrial flutter PMA application with the U.S. Food and Drug Administration (FDA). The FDA has recently notified the Company that it continues to actively review the Company's PMA following the submission of additional data in October 2005.

Biotech Intelligence (http://www.biotech-intelligence.com/html/html/cc0e3631c5907ae33bf5231475c36de9.html)